Project Grant R01HD114264
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $244,328 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to study the impact of in utero HIV and antiretroviral exposure on the placenta and birth weight. The key objectives are to simultaneously measure antiretroviral (ARV) levels in pregnant women and their children's hair to quantify drug exposure to...
- This federal Project Grant award of $1,332,155 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports a research initiative at Emory University to optimize immunotherapy strategies for achieving virologic control in HIV-infected infant macaques. The primary objectives are to evaluate the impact of activating the non-canonical NF-kB pathway, stimulating TLR7/8, and using the attachment inhibitor...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) provides $251,250.00 to the University of Massachusetts Medical School (UMass Medical) to support the planning and development of a proof-of-concept Phase I clinical trial. The trial will evaluate the safety, tolerability, and ability of a single administration of two AAV9-vectored broadly-neutralizing antibodies to enable sustained HIV-1 control in...
- This $232,500 Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) to The Johns Hopkins University supports research into the virologic determinants leading to long-term antiretroviral therapy-free control in infants with in utero HIV-1 infection. The study aims to create infectious molecular clones from proviral HIV-1 DNA in participants from the IMPAACT P1115...
- The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) awarded a $844,250 Project Grant under the Child Health and Human Development Extramural Research program (CFDA 93.865) to the University of Nebraska Medical Center (UNMC) on July 1, 2025. The grant funds a 2-year research project to develop a non-invasive magnetic resonance imaging (MRI) biomarker that can detect adverse neurodevelopmental effects in fetuses exposed to antiretroviral (ARV) drugs during...
- This $812,810 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research at Emory University to generate highly differentiated natural killer (NK) cells and evaluate their synergistic effects with broadly neutralizing antibodies in reducing the SIV reservoir and establishing viral control in the absence of antiretroviral therapy (ART). The key objectives are to: 1) define...
- This Project Grant award of $1,144,344 from the National Institute on Drug Abuse (NIDA)'s Drug Use and Addiction Research Programs (CFDA 93.279) supports research aimed at eliminating the central nervous system reservoir of simian immunodeficiency virus (SIV) in methamphetamine-exposed rhesus macaques receiving antiretroviral therapy. The Texas Biomedical Research Institute, doing business as the Southwest Foundation for Biomedical Research, will leverage novel AAV serotype gene therapy to...
- This federal Project Grant award of $499,140.00 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) will fund the "TSEPAMO NEXT GENERATION: OPTIMIZING HIV TREATMENT AND PREVENTION STRATEGIES FOR PREGNANT WOMEN IN BOTSWANA" research project at the Harvard T.H. Chan School of Public Health. The key objectives of this 5-year project are to: 1) investigate the safety and efficacy...
- This Cooperative Agreement award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) will provide $6,358,233 from September 2025 to August 2030 to President and Fellows of Harvard College to conduct the "Pediatric HIV/AIDS Cohort Study (PHACS): Research on Immune Aging, Sexual and Reproductive Health, and Perinatal Acquisition: Elucidating Relationships in...
- This federal Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the impact of a glucagon-like peptide-1 receptor agonist on pathogenesis and antiretroviral therapy (ART) administration in people living with HIV (PWH). The $780,853 award, with a period of performance from April 10, 2025 to March 31, 2030, will support research...
THE IMPACT OF ANTIRETROVIRAL THERAPY ON FETAL IMMUNE SYSTEM DEVELOPMENT IN SIV-EXPOSED RHESUS MACAQUES - SUMMARY THE USE OF ANTIRETROVIRAL THERAPY (ART) IN PREGNANT WOMEN LIVING WITH HIV IS AN EFFECTIVE WAY TO PREVENT MOTHER-TO-CHILD TRANSMISSION. HOWEVER, HIV-EXPOSED, BUT UNINFECTED (HEU) CHILDREN EXPERIENCE HIGHER MORTALITY FROM COMMON INFECTIONS AND SEVERE RESPIRATORY DISEASE. HOWEVER, THE INDEPENDENT AND COMBINATORIAL EFFECTS OF HIV AND ART ON FETAL IMMUNE CELL DEVELOPMENT REMAIN UNKNOWN. WE PROPOSE TO UTILIZE THE WELL-ESTABLISHED RHESUS MACAQUE MODEL OF ART-TREATED SIMIAN IMMUNODEFICIENCY VIRUS (SIV) INFECTION TO TEST OUR HYPOTHESIS THAT MATERNAL SIV AND ART EXERT DIFFERENTIAL EFFECTS ON THE DEVELOPMENT AND MATURATION OF THE FETAL IMMUNE SYSTEM, RESULTING IN DYSREGULATED FUNCTIONAL RESPONSES. TO ADDRESS THE DIFFERENTIAL EFFECTS OF SUPPRESSED SIV INFECTION AND ART, WE WILL STUDY THREE EXPERIMENTAL GROUPS OF FEMALES. IN THE SIV/ART GROUP, FEMALES WILL BE INFECTED WITH SIV AND THEN SUPPRESSED WITH ART BEFORE UNDERGOING TIMED-MATED BREEDING. WE WILL HAVE TWO CONTROL GROUPS: AN ART-ONLY GROUP AND AN UNTREATED/UNINFECTED HEALTHY PREGNANCY GROUP. WE ACKNOWLEDGE THAT THE ART-ONLY GROUP IS NOT A CLINICALLY RELEVANT SCENARIO, BUT NECESSARY IN THE CONTEXT OF THE PROPOSED STUDIES TO DISTINGUISH THE CONTRIBUTION OF ART PER SE TO THE FETAL IMMUNE PHENOTYPE EXHIBITED BY THE OFFSPRING OF SIV/ART DAMS. WE DO NOT HAVE AN UNTREATED SIV-INFECTED GROUP, AS THIS IS NOT RELEVANT TO THE VAST MAJORITY OF PREGNANT WLWH. GD130-135 FETUSES WILL BE OBTAINED VIA CAESAREAN SECTION AND STUDIED AS OUTLINED IN THE FOLLOWING SPECIFIC AIMS. AIM 1. DETERMINE THE EFFECTS OF MATERNAL SIV/ART OR ART ON FETAL IMMUNE SYSTEM FUNCTION. HEU CHILDREN EXHIBIT ALTERED LYMPHOCYTE FUNCTION AND BLUNTED RESPONSES OF MONOCYTES TO PATHOGENS. HOWEVER, LITTLE IS KNOWN ABOUT THE EFFECTS OF HIV/ART AND ART EXPOSURE ON LYMPHOID AND MYELOID CELL ACTIVATION DURING FETAL DEVELOPMENT. THEREFORE, WE WILL STUDY THE EFFECTS OF SIV/ART OR ART ON BOTH THE INNATE AND ADAPTIVE ARMS OF THE FETAL IMMUNE SYSTEM IN CIRCULATION AND IN FETAL TISSUES USING A COMBINATION OF FLOW CYTOMETRY, FUNCTIONAL ASSAYS, AND SINGLE-CELL TRANSCRIPTOMICS. AIM 2. DETERMINE THE EFFECTS OF MATERNAL SIV/ART OR ART ON FETAL HEMATOPOIESIS. SIV/ART OR ART MAY IMPACT FETAL IMMUNE SYSTEM DEVELOPMENT BY ALTERING FETAL HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCS). THEREFORE, IN THIS AIM, WE WILL ISOLATE HSPCS FROM THE FETAL LIVER AND FETAL BONES AND DETERMINE THE TRANSCRIPTIONAL LANDSCAPE AND FUNCTIONAL RECONSTITUTION ABILITIES OF HSPCS FROM SIV/ART, ART ALONE, AND CONTROL FETUSES. GIVEN THE INCREASINGLY PREVALENT USE OF ART IN WOMEN OF REPRODUCTIVE AGE, THIS STUDY WILL FURTHER OUR UNDERSTANDING OF THE EFFECT OF ART ON FETAL IMMUNE DEVELOPMENT. THE ULTIMATE GOAL OF THE PROPOSED STUDIES IS TO IDENTIFY FETAL IMMUNE SYSTEM DEVELOPMENTAL PATHWAYS THAT CAN BE TARGETED BY THERAPEUTICS AND INTERVENTIONS TO IMPROVE IMMUNE OUTCOMES FOR THIS VULNERABLE POPULATION OF INFANTS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.0m | 7/17/25 | ||
| Not listed | $0 | 7/15/25 | ||
| Not listed | $534.7k | 9/20/24 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
1025866UKYRFS | The University Of Kentucky Research Foundation | Project Grant R01HD114264 | $67.5k | 10/24/24 |